Navidea Biopharmaceuticals Inc ROCE
What is the ROCE of Navidea Biopharmaceuticals Inc?
The ROCE of Navidea Biopharmaceuticals Inc is 4,619.50%
What is the definition of ROCE?
Return on capital employed (ROCE) is a financial ratio that measures a company’s profitability and the efficiency with which its capital is used.
= EBIT / (assets - current liabilities)
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE of companies in the Health Care sector on NYSEMKT compared to Navidea Biopharmaceuticals Inc
What does Navidea Biopharmaceuticals Inc do?
navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de
Companies with roce similar to Navidea Biopharmaceuticals Inc
- GTPL Hathway has ROCE of 3,515.44%
- VBI Vaccines has ROCE of 3,542.31%
- North European Oil Royalty Trust has ROCE of 3,719.06%
- Pasofino Gold has ROCE of 3,729.38%
- Synthesis Systems has ROCE of 3,846.25%
- PhaseBio Pharmaceuticals has ROCE of 4,146.52%
- Navidea Biopharmaceuticals Inc has ROCE of 4,619.50%
- SRAX Inc has ROCE of 4,628.38%
- Blue Apron Inc has ROCE of 5,016.13%
- ParkerVision has ROCE of 5,589.92%
- Asensus Surgical Inc has ROCE of 5,861.92%
- Whiting USA Trust II has ROCE of 7,251.43%
- Astra has ROCE of 7,618.05%